Meeting
2018 Gastrointestinal Cancers Symposium
A SEER-based multiethnic picture of cholangiocarcinoma in the United States pre and post the advent of gemcitabine/cisplatin.
Authors
Kabir Mody
Mayo Clinic, Jacksonville, FL
Kabir Mody , Samuel O Antwi , David O Hodge , Zahara Meghji , Sikander Ailawadhi , Tanios S. Bekaii-Saab , Lewis R. Roberts
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 448)
DOI
10.1200/JCO.2018.36.4_suppl.448
Abstract #
448
Poster Bd #
L19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
LCK and resistance to cytotoxic chemotherapy via activating an AXL-PEAK1 signaling axis in cholangiocarcinoma.
First Author: Shohei Takaichi
Poster
2023 ASCO Annual Meeting
Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC).
First Author: Osama Aqel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Cost-effectiveness of gemcitabine plus cisplatin with and without durvalumab in patients with advanced cholangiocarcinoma.
First Author: J. Alberto Maldonado
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effect of AXL on cholangiocarcinoma survival and sensitivity to cytotoxic chemotherapy.
First Author: Shohei Takaichi